Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Based on this platform, we developed: (1) GT-02624, a GSPT1 molecular glue degrader with small size, degradation selectivity among the tested canonical CRBN neosubstrates and corresponding anti-proliferative activity; and (2) GT-01956, a BET-targeting PROTAC exhibiting picomolar degradation potency and exceptional anti-proliferative activity across hematologic and solid tumor cell lines.
| Market | Status | Year |
|---|---|---|
| United States | Not approved | — |
| European Union | Not approved | — |
| China | Not approved | — |
| Japan | Not approved | — |
Approved indications and other markets are in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on GT-02624.
Work on GT-02624? Claim this page to correct or add information. Claim this page